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Cloning of the gene responsible for cystic ﬁ brosis has 
led to remarkable advances in our understanding of 
the disease.1 Since then, roughly 2000 mutations have 
been identiﬁ ed in the cystic ﬁ brosis transmembrane 
conductance regulator (CFTR) gene. In the past decade, 
rapid progress has been made towards the development 
of CFTR treatments to target the basic defect in cystic 
ﬁ brosis.2–4 Ivacaftor was approved for patients with the 
Gly551Asp-CFTR mutation, which aﬀ ects about 3% of the 
global cystic ﬁ brosis population, and for patients with 
other CFTR-gating mutations. In May, 2015, Wainwright 
and colleagues reported results for the combination of 
ivacaftor and lumacaftor in patients homozygous for 
the phe508del mutation (about 50% of the global cystic 
ﬁ brosis population) and reported improved lung function 
(improvement in absolute forced expiratory volume in 
1 s [FEV1] % predicted 2·6–4·0 percentage points) and 
reduced pulmonary exacerbations (30–39% reduction) 
over 24 weeks.5 This combination of ivacaftor and 
lumacaftor has since been approved by the US Food and 
Drug Administration, under the trade name Orkambi.
Soon after discovery of the cystic ﬁ brosis gene, initial 
enthusiasm for the potential role of gene therapy to cure 
cystic ﬁ brosis was quickly dampened by the complexity 
of replacement of the defective CFTR protein. Many 
challenges were identiﬁ ed, including determining the 
optimum vector for gene transfer based on studies of 
safety, how to ensure enduring gene expression, and 
how to restrict systemic inﬂ ammatory responses. To 
date, more than 25 clinical trials have been completed, 
with most being of short duration with small populations 
and undertaken to examine safety or the extent of gene 
transfer.6 Established in 2001, the UK Cystic Fibrosis Gene 
Therapy Consortium has pioneered the development of 
non-viral approaches for gene therapy. The Consortium 
has led pre-clinical and early phase clinical trials to 
optimise vector formulation, gene dosing, delivery 
modes, safety, and the establishment of endpoints for 
eﬃ  cacy studies.
In The Lancet Respiratory Medicine, Eric Alton and 
colleagues7 report the results of a randomised, double-
blind, placebo-controlled, phase 2b study of multi-dose 
nebulised gene–liposome complex (pGM169/GL67A) in 
patients with cystic ﬁ brosis (FEV1 50–90% predicted) and 
any combination of CFTR mutation. Monthly application 
of pGM169/GL67A was associated with a signiﬁ cant 
beneﬁ t in FEV1 compared with placebo at 12 months’ 
follow up (3·7%, 95% CI 0·1–7·3%; p=0·046). Importantly, 
therapy with pGM169/GL67A was well tolerated, with no 
excess treatment-associated adverse eﬀ ects. Secondary 
endpoints did not diﬀ er signiﬁ cantly between gene 
therapy and placebo groups. Several substudies, including 
nasal and lower airway gene transfer analyses, showed 
modest concentrations of pGM169 plasmid DNA. In a 
post-hoc analysis, of the roughly one in ﬁ ve participants 
who had an improvement in FEV1 of more than 5%, 70% 
received the gene–liposome complex. Another notable 
ﬁ nding was that patients with more severe lung disease 
(FEV1 49·6–69·2% predicted) tended to have a greater 
treatment eﬀ ect (6·4%) than those with milder lung 
disease (FEV1 69·6–89·9% predicted; treatment eﬀ ect 
0·2%; p=0·065). This outcome warrants further study to 
establish whether this result can be replicated. 
This study represents the most recent scientiﬁ c output 
following almost 15 years of intensive preparatory work, 
but the path travelled by the Consortium has not always 
been smooth. In 2011, the viability of the trial was at risk 
because of a funding shortfall.8 Further funding from the 
Medical Research Council and the National Institute for 
Medical Research enabled the programme to continue. 
Although the ﬁ ndings of this study are modest, it is 
important to acknowledge the crucial preparatory work 
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and its potential to provide important direction for 
future clinical trials. Online supplementary ﬁ les for many 
publications are obscure to many readers and are often the 
reserve of scientists working directly in the ﬁ eld. I would 
encourage readers to delve into this online supplementary 
ﬁ le (the appendix) because it provides insights into 
the logistical triumph in successful completion of this 
study, and into the potential challenges of moving such 
therapies into the clinic.
Several aspects of the study design and its ﬁ ndings are 
worthy of further consideration. The ﬁ rst point is the use 
of nebulised physiological saline as placebo, motivated by 
inadequate funding and potential risks. The larger than 
anticipated decline in lung function in the placebo group 
would argue against a favourable eﬀ ect of physiological 
saline. Future gene therapy trials should include a CFTR-
depleted plasma–liposome complex because this study 
was completed without major safety signals. Rates of 
lung-function decline have been decreasing in the cystic 
ﬁ brosis population (FEV1 about 1% predicted per year).9 
In view of this, the lung function decline in the placebo 
group in this trial was surprisingly large. Alton and 
colleagues argue that this ﬁ nding might be explained by 
participants’ increasing health maintenance during the 
pre-screening period to fulﬁ l trial inclusion criteria and this 
was not able to be sustained during the 12 month study 
period. Another clinical trial10 has reported a similar rate of 
lung function decline as reported in the present study, but 
other trials have reported lower rates of decline.2-5 Notably, 
health-related quality of life was not improved by gene 
therapy, despite improved lung function. Future studies 
should examine the eﬀ ect on pulmonary exacerbations 
(which was not an endpoint here) and patient-reported 
outcomes including health-related quality of life.
Ironically, there has been a rapid increase in clinical 
trials to address CFTR over the past decade, creating 
competition for trial participants despite coordinating 
cystic ﬁ brosis trial networks.11,12 This situation is 
exempliﬁ ed by the observation that three trial participants 
withdrew from Alton and colleagues’ study to begin 
ivacaftor treatment. Nevertheless, for about 50% of 
the cystic ﬁ brosis population for whom no evidence 
for pharmacological correction yet exists, a therapy 
that is potentially suitable for patients with any CFTR 
combination is of great interest. The next step that these 
authors will take is worth considering. The investigators 
sagely do not recommend moving to a phase 3 trial, but 
rather emphasise the need to assess more eﬀ ective gene-
transfer vectors. This assessment might include revisiting 
viral vectors, such as lentiviral platforms.6,13
Finally, whilst acknowledging the early and yet 
substantial steps in the development of eﬀ ective CFTR 
therapies for people with cystic ﬁ brosis, awareness is 
growing of the complexity of the interactions between 
the CFTR protein and complex intracellular protein 
networks.14,15 An even broader understanding of the 
cellular biology of CFTR is needed for successful correction 
of the numerous CFTR mutations.  
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